15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression

Abstract

Aim:

The aim of this study is to investigate the efficacy and safety of long-term therapy with Serenoa repens extract with regard to halting benign prostatic hyperplasia progression.

Material and methods:

An open non-comparative observational study of the continuous use of S. repens plant extract at a dosage of 320 mg once a day for 15 years was performed in 30 patients at risk for benign prostatic hyperplasia progression. Changes in IPSS (International Prostatic Symptoms Scale) and QoL (Quality of life) scores and changes in Qmax, voided volume, residual urine volume, and prostate volume were evaluated during the study.

Results:

The study showed an absence of progression based on both subjective (the sum of scores on the IPSS and QoL scales) and objective (prostate volume, urination rate, residual urine volume) criteria. Furthermore, the patients had no adverse events related to the study drug, including prostate cancer.

Conclusions:

The 15 years’ study results suggest that taking S. repens plant extract continuously at a daily dose of 320 mg is an effective and safe way to prevent the progression of benign prostatic hyperplasia.

Keywords

Benign prostatic hyperplasia risk of progression continuous use plant extracts

Get full access to this article

View all access options for this article.

References

De la Rosette

Alivizatos

Madersbacher

et al . Guidelines on benign prostatic hyperplasia. Arnhem: European Association of Urology, 2002.

Jacobsen

Girman

Guess

et al . Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595–600.

McConnell

Bruskewitz

Walsh

et al . The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study. New Engl J Med 1998; 338: 557–563.

Roehrborn

Boyle

Bergner

et al . Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54: 662–669.

Rhodes

Girman

Jacobsen

et al . Longitudinal prostate volume in a community-based sample: 7 year followup in the Olmsted County Study of urinary symptoms and health status among men. J Urol 2000; 163(Suppl. 4): 249.

Medvedev

. Serenoa repens extract in treatment of benign prostatic hyperplasia. Dissertation, Moscow, 2011.

Vinarov

Lokshin

et al . Five-year experience of treatment with permixon patients with prostate hyperplasia (Serenoa repens, “Pierre Fabre Medicament”). Urology 2002; 1: 23–25.

Vinarov

Lokshin

et al . Efficacy and safety of prostamol-Uno in patients with chronic abacterial prostatitis. Urology 2006; 1: 47–50.

Mazo

Dmitriev

. Clinical effect of using the drug “prostamol-Uno” in patients with benign prostatic hyperplasia and chronic prostatitis. Urology 2001; 5: 38–41.

10.

Mazo

Popov

. “Prostamol Uno” in prolonged and continuous treatment of patients with benign prostatic hyperplasia and chronic prostatitis. RMJ 2007; 15(13): 972–978.

11.

Trapeznikova

Dutov

Dolgov

. The use of “prostamol Uno” in the treatment of patients with benign prostatic hyperplasia and chronic prostatitis. Vrach Soslovie 2007; 3: 42–43.

12.

Razumov

Derevianko

Sivkov

. Prostamol Uno in the treatment of patients with benign prostatic hyperplasia. Urology 2001; 2: 35–37.

13.

Di Silverio

Monti

Sciarra

et al . Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37: 77–83.